Our focus on pushing the frontier of CAR therapies has led to several paradigm-shifting innovations including CART123 for acute myeloid leukemia, CAR macrophages for solid tumors, and pairing CART33 treatment with CRISPR-edited CD33-deficient bone marrow transplants. Each of these technologies is currently being pursued in early phase clinical trials, and promises to alter the landscape of cancer immunotherapy and pave the way for further innovation.